Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

NCT07115082

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Yan Hongli
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (5)

- The intention of pregnant women aged \>= 20 and \< 40, with normal karyotype;
- Oligo/amenorrhea for at least 4 months;
- Elevated FSH level \>25 IU/l on two occasions \>4 weeks apart;
- Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months;
- Voluntary participation in the study with signed informed consent;

Exclusion (10)

- Unable to follow the treatment observation process required by the trial;
- Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure;
- With breast, uterine, ovarian tumors, or any other benign or malignant tumors;
- Allergic history to drugs or any other things;
- Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs.

... and 5 more (see full listing online)

Locations (1 total)

Shanghai Changhai Hospital, Shanghai, China

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.